Carminomycin, 14-hydroxycarminomycin and its novel carbohydrate derivatives potently kill human tumor cells and their multidrug resistant variants

Journal of Antibiotics

Volumn 57, Issue 2, 2004, Pages 143-150

  Tevyashova, Anna N ^a   Shtil, Alexander A ^b   Olsufyeva, Eugenia N ^a   Simonova, Valeria S ^b   Samusenko, Alexei V ^b   Preobrazhenskaya, Maria N ^a  

^a GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

14 HYDROXYCARMINOMYCIN DERIVATIVE; 14 HYDROXYCARUBICIN; 3' N (1 DESOXY DEXTRO GALACTIT 1 YL) 14 HYDROXYCARMINOMYCIN; 3' N [ ALPHA DEXTRO (GALACTOPYRANOSYL (1-6) O 1 DESOXYGLUCIT 1 YL)] 14 HYDROXYCARMINOMYCIN; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC ANTIBIOTIC; CARBOHYDRATE DERIVATIVE; CARUBICIN; DAUNORUBICIN; DOXORUBICIN; DOXORUBICIN DERIVATIVE; GALACTOSE; MELIBIOSE; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG HYDROLYSIS; DRUG POTENCY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROPHILICITY; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; THIN LAYER CHROMATOGRAPHY; TUMOR CELL CULTURE; WILD TYPE;

EID: 1642523684     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.7164/antibiotics.57.143     Document Type: Article

References (27)

1. Ambudkar, S. V.; S. Dey, C. A. Hrycyna, M. Ramachandra, I. Pastan & M. M. Gottesman: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39: 361-398, 1999
2. Covelli, A.: Modulation of multidrug resistance (MDR) in hematological malignancies. Ann. Oncol. 10 (Suppl. 6): 53-59, 1999
3. Galani, E.; J. Sgouros, C. Petropoulu, J. Janinis, G. Arayantinos, D. Dionysious-Asteriou, D. Skarlos & E. Gonos: Correlation of MDR-1, nm23-H1 and H Sema E gene expression with histopathological findings and clinical outcome in ovarian and breast cancer patients. Anticancer Res. 22: 2275-2280, 2002
4. Charpin, C.; P. Vielh, F. Duffraud, B. Devictor, L. Andrac, M. N. Lavaut, C. Allasia, N. Horschowski & L. Piana: Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators. J. Natl. Cancer Inst. 86: 1539-1545, 1994
5. Van Zuylen, L.; K. Nooter, A. Sparreboom & J. Verweij: Development of multidrug-resistance convertors: Sense or nonsense? Invest. New Drugs 18: 205-220, 2000
6. Gause, G. F.; L. P. Terekhova, T. S. Maksimova, O. L. Olkhovatova, N. V. Lavrova, M. G. Brazhnikova, N. V. Konstantinova, T. M. Myshentseva & E. N. Olsufieva: Actinomyces Cremeospinus sp. nov., a new carminomycin-producing organism. Antibiotiki (Russ.) 20: 389-393, 1975
7. Povarov, L. S.; V. S. Bazhanov & V. F. Vasekina: Obtaining of 14-oxycarminomycin and study of its antitumor activity. Antibiotiki (Russ.) 22: 693-695, 1977
8. Povarov, L. S.; O. V. Leont'eva, R. J. Bernacki, E. N. Olsuf'eva, E. I. Salimova, P. Pera & M. N. Preobrazhenskaya: 14-Esters and 13-hydrazones of anthracycline antibiotics of the daunorubicin series: Synthesis and cytostatic activity toward tumor. cells sensitive or resistant to doxorubicin. Rus. J. Bioorg. Chem. 21: 797-803, 1995
9. Gause, G. F.: In Antitumor antibiotic carminomycin in clinic. Ed., G. F. Gause, Russian. Academy of Medical Sciences, N. Blokhin Cancer Center, Moscow, 1980
10. Olsufyeva, E. N.; A. N. Tevyashova, I. D. Trestchalin, M. N. Preobrazhenskaya, D. Platt & A. Klyosov: Synthesis and antitumor activity of new D-galactose containing derivatives of doxorubicin. Carbohydrate Res. 338: 1359-1367, 2003
11. Mechetner, E. B.; B. Schott, B. S. Morse, W. D. Stein, T. Druley, K. A. Davis, T. Tsuruo & I. B. Roninson: P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proc. Natl. Acad. Sci. USA 94: 12908-12913, 1997
12. Mossman, T.: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55-63, 1983
13. Sidorova, T. A.; A. Nigmatov, E. S. Kakpakova, A. A. Stavrovskaya, G. K. Gerassimova, A. A. Shtil & E. P. Serebryakov: Effects of isoprenoid analogues of SDB-ethylenediamine on multidrug resistant tumor cells alone and in combination with chemotherapeutic drugs. J. Med. Chem. 21: 5330-5339, 2002
14. Olsuf'eva, E. N. & B. V. Rozynov: Synthesis and mass spectrometry evaluation of N-cycloalkyl derivatives of carminomycin, daunorubicin and their analogues. Soviet J. Bioorg. Chemistry 16: 847-853, 1991
15. Povarov, L. S.; N. I. Isaeyava, L. M. Rubasheva & E. N. Olsufyeva: The unusual reaction of bromination of ketone. Zhurnal Org. Khimii (Russ) 15: 1560-1561, 1979
16. Tsuruo, T.: Reversal of multidrug resistance by calcium channel blockers and other agents. In Molecular and cellular biology of multidrug resistance in tumor cells. Ed., I. B. Roninson, pp. 349-372. Plenum Press, New York & London, 1991
17. Smyth, M. J.; E. Krasovskis, V. R. Sutton & R. W. Johnstone: The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc. Natl Acad. Sci. USA 95: 7024-7029, 1998
18. Johnstone, R. W.; E. Cretney & M. J. Smyth: P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93: 1075-1085, 1993
19. Zunino, F.; G. Pratesi & P. Perego: Role of the sugar moiety in the pharmacological activity of anthracyclines: Development of a novel series of disaccharide analogs. Biochem. Pharmacol. 61: 933-938, 2001
20. Garnier-Suillerot, A.; C. Marbeuf-Gueye, M. Salerno, C. Loetchuitinat, I. Fokt, M. Krawczyk, T. Kowalczyk & W. Priebe: Analysis of drug transport kinetics in multidrug-resistant cells: Implications for drug action. Current Med. Chem. 8: 51-64, 2001
21. Leontieva, O. V.; M. N. Preobrazhenskaya & R. J. Bernacki: Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate. Invest New Drugs 20: 35-48, 2002
22. Shorin, V. A.; V. S. Bazhanov & L. A. Averbukh: Antitumor activity of carminomycin used perorally. Antibiotics 2: 1005-1007, 1976
23. Seeber, S.: Nuclear and cellular accumulation of aclacinomycin A, AD32, carminomycin and marcellomycin in daunorubicin-sensitive (EAC-S) and -resistant (EAC-DNM) Ehrich ascites. Proc. Amer. Ass. Cancer Res. 21: 272, 1980
24. Baldini, N.: Multidrug resistance - a multiplex phenomenon. Nature (Med) 3: 378-380, 1997
25. Neubauer, A.; M. He, C. A. Schmidt, D. Huhn & E. T. Liu: Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: Analysis by polymerase chain reaction based techniques. Leukemia 7: 593-600, 1993
26. Danhauser-Riedl, S.; M. Warmuth, B. J. Druker, B. Emmerich & M. Hallek: Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res. 56: 3589-3596, 1996
27. Janicke, R. U.; M. L. Sprengart, M. R. Wati & A. G. Porter: Caspase-3 is required-for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem. 273: 9357-9360, 1998